4.7 Article

Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis

期刊

NEUROLOGY
卷 76, 期 14, 页码 1206-1213

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0b013e31821432ff

关键词

-

资金

  1. Swiss Multiple Sclerosis Society
  2. Novartis
  3. Dutch MS Research Foundation
  4. Roche
  5. Medical Research Council UK
  6. European Union
  7. Biotechnology and Biological Sciences Research Council (BBSRC) UK DTG
  8. Lille2 University
  9. Swiss National Research Foundation
  10. Swiss MS Society
  11. Gianni Rubatto Foundation (Zurich)
  12. Acorda Therapeutics Inc.
  13. Actelion Pharmaceuticals Ltd
  14. Abbott
  15. Abbott, AstraZeneca
  16. Bayhill Therapeutics
  17. Bayer Schering Pharma
  18. Biogen Idec
  19. Boehringer Ingelheim
  20. Centocor Ortho Biotech Inc.
  21. Eisai Inc.
  22. Genzyme Corporation
  23. GlaxoSmithKline
  24. Immune Response Corporation
  25. MediciNova, Inc.
  26. Neurocrine Biosciences
  27. Sanofi-Aventis
  28. Merck Serono
  29. Teva Pharmaceutical Industries Ltd.
  30. UCB
  31. Wyeth

向作者/读者索取更多资源

Objective: Neurodegeneration is now accepted as a pathologic hallmark of multiple sclerosis (MS). We sought to discover whether CSF levels of neurofilament heavy chain protein (NfH(SMI35)) correlate with disability, disease activity, or specific stages of MS. Methods: An electrochemiluminescence immunoassay was used to retrospectively measure NfHSMI35 in CSF of patients with clinically isolated syndrome (CIS) (n = 63), relapsing-remitting multiple sclerosis (RRMS) (n = 39), secondary progressive multiple sclerosis (SPMS) (n = 25), primary progressive multiple sclerosis (PPMS) (n = 23), or controls (n = 73). Cell count and CSF levels of immunoglobulin and albumin were also measured. Results: CSF levels of NfH(SMI35) increased with age in controls (r(s) = 0.50, p < 0.0001) and CIS (r(s) = 0.50, p < 0.0001); this effect was less pronounced in RRMS (r(s) = 0.35, p = 0.027) and absent in SPMS/PPMS. After age correction, NfH(SMI35) levels were found to be higher in all disease stages compared to control. Relapses were associated with higher CSF NfH(SMI35) values compared with stable disease. NfH(SMI35) levels correlated with EDSS scores in patients with CIS and RRMS (r(s) = 0.33, p = 0.001), and during relapse (r(s) = 0.35, p = 0.01); the correlation was most prominent in RRMS during relapse (r(s) = 0.54, p = 0.01). This was not the case for any of the other CSF markers examined. Conclusions: Neuronal loss is a feature of aging, and the age-dependent increase of CSF NfH(SMI35) suggests that this loss accelerates over time. For MS, increased NfH(SMI35) levels reflect the superimposed presence of further neurodegenerative processes. Evaluation of NfH(SMI35) levels is likely to provide a useful surrogate for measuring the rate of neurodegeneration in MS. Furthermore, the dissociation of NfH(SMI35) levels with biomarkers of inflammation suggests that the mechanisms responsible for their production are at least partly independent. Neurology (R) 2011;76:1206-1213

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据